Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The investigators aimed to accurately measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.
In patients with operable breast cancer (BC) receiving neoadjuvant chemotherapy (NAC), the pathological response rate was found to be related to body composition. The success of complete pathologic response (pCR) is a known prognostic factor in BC patients treated with NAC. The investigators aimed to accurately measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Pathologic complete response (pCR) | Patient with complete pathological response |
| |
| Pathologic incomplete response (non-pCR) | Patient with partial pathological response |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Neoadjuvant therapy | Other | To measure muscle mass and predict pCR to NAC and its effect on clinical outcomes. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Sarcopenic index | skeletal muscle area (cm2)/height (m2) et L3 level | Through study completion, an average of 1 year. |
| Measure | Description | Time Frame |
|---|---|---|
| Body mass index | weight (kg)/height (m2) | Through study completion, an average of 1 year. |
| Measure | Description | Time Frame |
|---|---|---|
| Residual cancer burden | Residual cancer burden (RCB) is estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. | Through study completion, an average of 1 year. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Early and locally advanced operated breast cancer patients receiving neoadjuvant chemotherapy.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Aysun Isiklar, M.D. | Acıbadem Atunizade Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| AcıbademAH | Istanbul | 34782 | Turkey (Türkiye) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D020360 | Neoadjuvant Therapy |
| ID | Term |
|---|---|
| D003131 | Combined Modality Therapy |
| D013812 | Therapeutics |
Not provided
Not provided
Not provided
Not provided
Not provided